allyl-biphenyl-3-yl ether | 905563-18-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: allyl-biphenyl-3-yl ether
• 英文别名: Allyl-biphenyl-3-yl-aether；3-(2-propenyloxy)biphenyl；1-phenyl-3-prop-2-enoxybenzene
• CAS: 905563-18-0
• 化学式: C₁₅H₁₄O
• 分子量: 210.276
• InChiKey: DEUSYQAAFHYUQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  allyl-biphenyl-3-yl ether 在 吡啶盐酸盐 作用下， 生成 2-methyl-6-phenyl-2,3-dihydro-benzofuran
  参考文献：
  名称：

  Substituted 2,3-dihydro-2-methylbenzofurans

  摘要：

  公开号：

  US02548704A1
• 作为产物：
  描述：

  间羟基联苯 、 3-氯丙烯 在 sodium hydroxide 作用下， 生成 allyl-biphenyl-3-yl ether
  参考文献：
  名称：

  Substituted 2,3-dihydro-2-methylbenzofurans

  摘要：

  公开号：

  US02548704A1

文献信息

• Small Molecule NF-κB Inhibitors as Immune Potentiators for Enhancement of Vaccine Adjuvants
  作者：Brittany A. Moser、Yoseline Escalante-Buendia、Rachel C. Steinhardt、Matthew G. Rosenberger、Britteny J. Cassaidy、Nihesh Naorem、Alfred C. Chon、Minh H. Nguyen、Ngoctran T. Tran、Aaron P. Esser-Kahn

  DOI：10.3389/fimmu.2020.511513

  日期：——

  Adjuvants are added to vaccines to enhance the immune response and provide increased protection against disease. In the last decade, hundreds of synthetic immune adjuvants have been created, but many induce undesirable levels of proinflammatory cytokines including TNF-α and IL-6. Here we present small molecule NF-κB inhibitors that can be used in combination with an immune adjuvant to both decrease

  疫苗中添加佐剂可增强免疫反应并增强对疾病的保护。在过去的十年中，数百种合成免疫佐剂被创造出来，但许多都会诱导促炎细胞因子（包括 TNF-α 和 IL-6）达到不良水平。在这里，我们提出了小分子 NF-κB 抑制剂，可与免疫佐剂联合使用，以减少与耐受性差相关的标记物并改善疫苗接种的保护反应。此外，我们合成了和厚朴酚衍生物库，确定了几种有希望用于疫苗制剂的候选物。
• 1-(Piperidin-4- Yl)-1H-Indole Derivatives
  申请人：Suzuki Yuichi

  公开号：US20080119518A1

  公开（公告）日：2008-05-22

  The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.): [wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula: wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, etc.]

  本发明提供了一种由式(1)表示的化合物或其药学上可接受的盐，或其水合物（前提是排除所有R4a、R4b和R4c均为氢原子的化合物）：[其中R1表示氢原子，R2表示氢原子，R3表示式：其中R4a、R4b和R4c相同或不同，且每个表示氢原子、C1-6烷基或C1-6烷氧基等。]
• 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1847535A1

  公开（公告）日：2007-10-24

  The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.): [wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula: wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, etc.]

  本发明提供了一种由式（1）表示的化合物或其药理学上可接受的盐，或其水合物（但不包括R4a、R4b和R4c全部为氢原子的化合物）： [其中 R1 代表氢原子，R2 代表氢原子，R3 代表式（1）： 其中 R4a、R4b 和 R4c 彼此相同或不同，且各自代表氢原子、C1-6 烷基或 C1-6 烷氧基等]。
• EP1847535
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of honokiol analogues and evaluation of their modulating action on VEGF protein secretion and telomerase-related gene expressions
  作者：María Sánchez-Peris、Juan Murga、Eva Falomir、Miguel Carda、Juan Alberto Marco

  DOI：10.1111/cbdd.12880

  日期：2017.4

  A group of 36 biphenyl derivatives structurally related to honokiol were synthesized by means of Suzuki coupling reactions. Their cytotoxicities were evaluated and compared to that of honokiol. Some of the compounds were then evaluated for their ability to downregulate the secretion of the VEGF protein and the expression of the VEGF, hTERT, and c‐Myc genes; the two latter involved in the activation of telomerase in tumoral cells. Some of the synthetized derivatives showed promising pharmacological features as they exhibited IC50 values in low micromolar range, good therapeutic margins, and a multiple mode of action on tumor cells based on the inhibition of VEGF and, at the same time, of the expression of genes related to the activation of telomerase.